Skip to main content
SpringerLink
Log in

Prevention of Atherothrombotic Brain Infarction: Role of Lipids

  • Chapter
Prevention of Stroke

  • 164 Accesses

Abstract

Atherothrombotic brain infarction (ABI) is the primary cause of stroke both in the Western and Eastern worlds. The apparent successes of interventional measures in averting coronary atherosclerosis has fueled interest and optimism in applying these strategies to ABIs, both for primary and secondary prevention.1 The magnitude of ABIs worldwide and the frustration in having no reliable or effective acute therapies to prevent ischemic brain injury have led to greater efforts to reduce the primary disease of atherosclerosis.1 Therapeutic approaches in the past for ABI prevention have evolved behind those for coronary heart disease (CHD) and include surgical, medical, and “holistic” interventions through risk reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Yatsu FM, Fisher M. Atherosclerosis: current concepts on pathogenesis and interventional therapies. Ann Neurol. 1989;26:3–12.

    Article  PubMed  CAS  Google Scholar 

  2. Grotta JC. Current medical and surgical therapy for cerebrovascular disease. N Engl J Med. 1987;316: 1505–1516.

    Article  Google Scholar 

  3. The Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomization prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke. 1989;20:844–849.

    Article  Google Scholar 

  4. The EC/IC bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med. 1985;313:1191–1200.

    Article  Google Scholar 

  5. Fields WS, Lemak NA, et al. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301–316.

    Article  PubMed  CAS  Google Scholar 

  6. The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia, part IL Endpoint results. Stroke. 1985; 16: 406–415.

    Article  Google Scholar 

  7. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. Br Med J. 1988;296:316–320.

    Article  Google Scholar 

  8. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing Ticlopidine Hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–507.

    Article  PubMed  CAS  Google Scholar 

  9. Grundy SM, Greenland P, et al. Cardiovascular and risk factor evaluation of healthy American adults-a statement for physicians by an ad hoc committee appointed by the steering committee, American Heart Association. Circulation. 1987; 75:1340A- 1362A.

    PubMed  CAS  Google Scholar 

  10. Kannel WB, McGee DC. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038.

    Article  PubMed  CAS  Google Scholar 

  11. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;8:77–88.

    Google Scholar 

  12. Castelli WP, Garrison RJ, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256: 2835–2838.

    Article  PubMed  CAS  Google Scholar 

  13. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374.

    Article  Google Scholar 

  14. Leon AS, Connett J, et al. Leisure-time physical activity levels and risk of coronary heart disease and death: The multiple risk factor intervention trial. JAMA. 1987;258:2388–2395.

    Article  PubMed  CAS  Google Scholar 

  15. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in the development of cardiovascular disease. Am Heart J. 1985;109:876–885.

    Article  PubMed  CAS  Google Scholar 

  16. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings: III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:663–683.

    Google Scholar 

  17. Whelton PK. Declining mortality from hypertension and stroke. South Med J. 1982;75:33–38.

    Article  PubMed  CAS  Google Scholar 

  18. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251: 351–364.

    Article  Google Scholar 

  19. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317: 1237 - 1245.

    Article  PubMed  CAS  Google Scholar 

  20. Grotta JC, Yatsu FM, et al. Prediction of carotid stenosis progression by lipid and hematological measurements. Neurology. 1989;39:1325–1331.

    Article  PubMed  CAS  Google Scholar 

  21. Yatsu FM, Becker C, McLeroy KR, et al. Community hospital based stroke programs: North Carolina, Oregon and New York: I. Goals, objectives and data collection procedures. Stroke. 1986;17:276–284.

    Article  PubMed  CAS  Google Scholar 

  22. Abbott RD, Donahue RP, et al. Diabetes and the risk of stroke: the Honolulu heart program. JAMA. 1987;257:949–952.

    Article  PubMed  CAS  Google Scholar 

  23. Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity and risk of stroke: the Framingham study. JAMA. 1981 ;245:1225–1229.

    Article  PubMed  CAS  Google Scholar 

  24. Price TR, Dambrosia J, et al. Early determination of prognosis for 30 day and 1 year survival in ischemic infarction. The NINCDS stroke data bank. Neurology. 1985;35 (suppl 1):212.

    Article  Google Scholar 

  25. Sacco RL, Foulkes MA, Mohr JP, et al. Determinants of early recurrence of cerebral infarction: stroke data bank. Stroke. 1988; 19:144.

    Google Scholar 

  26. Dexter DD Jr, Whisnant JP, et al. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc. 1987;62:1077–1083.

    Article  PubMed  Google Scholar 

  27. Abbott RD, Yin Y, Reed DM, et al. Risk of stroke in male cigarette smokers. N Engl J Med. 1986; 315:717–720.

    Article  PubMed  CAS  Google Scholar 

  28. Stampfer MJ, Colditz GA, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 1988;319:267–213.

    Article  PubMed  CAS  Google Scholar 

  29. Gill J, Zezuika, AV, et al. Stroke and alcohol consumption. N Engl J Med. 1986;315:1041–1046.

    Article  PubMed  CAS  Google Scholar 

  30. Fry DL, Manley RW, Oh SY, Smyt CR. Aortic transmural serum protein transport: effect of concentration time and location. Am J Physiology. 1981;241:1454–1461.

    Google Scholar 

  31. Gordon, T. The Framingham diet study: diet and the regulation of serum cholesterol. In: Kannel WB, Gordon T, eds. Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Section 24. Washington, DC: Government Printing Office; 1970.

    Google Scholar 

  32. Steinberg D. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 1987;76:508–514.

    Article  PubMed  CAS  Google Scholar 

  33. Mahley RW. Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am. 1982;66:375–400.

    PubMed  CAS  Google Scholar 

  34. Ross R. The pathogenesis of atherosclerosis —an update. N Engl J Med. 1986;295:369–377.

    Article  Google Scholar 

  35. Jonasson L, Holm J, Skalli O, et al. Regional accumulation of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131–138.

    Article  PubMed  CAS  Google Scholar 

  36. Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 1974;71:1207–1210.

    Article  PubMed  CAS  Google Scholar 

  37. Joris I, Zand T, Nunnari JJ, et al. Studies on the pathogenesis of atherosclerosis: I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol. 1983; 113: 341–385.

    PubMed  CAS  Google Scholar 

  38. Brown MS, Goldstein JL. Lipoprotein metabolism in macrophages: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52: 223–261.

    Article  PubMed  CAS  Google Scholar 

  39. Fielding CJ, Fielding PE. Cholesterol transport between cells and body fluids. Med Clin North Am. 1982;66:363–373.

    PubMed  CAS  Google Scholar 

  40. Schmitz G, Niemann R, Brennhausen B, et al. Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA: cholesterol acyltransferase. EMBO J. 1985;4:2773–2779.

    PubMed  CAS  Google Scholar 

  41. Stein O, Halperin G, Stein Y: Cholesteryl ester efflux from extracellular and cellular elements of the arterial wall. Arteriosclerosis. 1986;6:70–78.

    Article  PubMed  CAS  Google Scholar 

  42. Miller GM, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1975;1:16–18.

    Article  PubMed  CAS  Google Scholar 

  43. Rossner S, Kjellin KG, Mettinger KL, et al. Normal serum cholesterol but low high density lipoprotein cholesterol concentrations in young patients with ischaemic cerebrovascular disease. Lancet. 1978; 1: 577–579.

    Article  PubMed  CAS  Google Scholar 

  44. Sirtori CR, Gainfrancheschi G, Gritti I, et al. Decreased levels of high-density lipoprotein cholesterol levels in male patients with transient ischemic attacks. Atherosclerosis. 1979;30:205–211.

    Article  Google Scholar 

  45. Taggart H, Stout RW. Reduced high density lipoprotein in stroke: relationship with elevated triglyceride and hypertension. Eur J Clin Invest. 1979; 9:219–221.

    Article  PubMed  CAS  Google Scholar 

  46. Noma A, Matshushita S, Komori T, et al. High and low density lipoprotein cholesterol in myocardial and cerebral infarction. Atherosclerosis. 1979;32: 327–331.

    Article  PubMed  CAS  Google Scholar 

  47. Nubiola AR, Masana L, Masdeu S, et al. High density lipoprotein but low high density lipoprotein cholesterol concentrations in young patients with ischaemic cerebrovascular disease. Lancet. 1978; 1: 577–579.

    Google Scholar 

  48. Bihari-Varga M, Szekely J, Gruber E. Plasma high density lipoproteins in coronary, cerebral and peripheral vascular disease: the influence of various risk factors. Atherosclerosis. 1981;40:337–345.

    Article  PubMed  CAS  Google Scholar 

  49. Murai A, Tanaka T, Miyahara T, Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke. 1981;12:167–172.

    Article  PubMed  CAS  Google Scholar 

  50. Brinton, EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-l and A-II fractional catabolic rate in women. J Clin Invest. 1989; 84:262–269.

    Article  PubMed  CAS  Google Scholar 

  51. Yatsu FM, Alam R, Alam S. Scavenger activity in monocyte-derived macrophages from atherothrom-botic strokes. Stroke. 1986;17:709–713.

    Article  PubMed  CAS  Google Scholar 

  52. Hartung HP, Kladetzky RG, Melnik B, et al. Stimulation of the scavenger receptor on monocyte-macrophage evokes release of arachidonic acid metabolites and reduced oxygen species. Lab Invest. 1986;55:209–216.

    PubMed  CAS  Google Scholar 

  53. Gerrity RG. The role of the monocyte in atherogene-sis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981; 103:181–190.

    PubMed  CAS  Google Scholar 

  54. Van Lenten BJ, Fogelman AM, Jackson RL, et al. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. J Biol Chem. 1985;260:8783–8788.

    PubMed  Google Scholar 

  55. Wissler RW. Principles of the pathogenesis of atherosclerosis. In: Braunwald E. ed. Heart Disease. Philadelphia, PA: W.B. Saunders Co.; 1980: pp 1221–1245.

    Google Scholar 

  56. Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate: II. Fatty streak conversion to fibrous plaque. Arteriosclerosis. 1984;45:341–356.

    Google Scholar 

  57. Malinow MR, Blaton V. Regression of atherosclerotic lesions. Arteriosclerosis. 1984;4:292–295.

    Article  PubMed  CAS  Google Scholar 

  58. Salonen JT, Puska P, Mustaniemi H. Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–77 in North Karelia. Br Med J. 1979;2:1178–1183.

    Article  PubMed  CAS  Google Scholar 

  59. West RO, Hayes OB. Diet and serum cholesterol levels: a comparison between vegetarians and non-vegetarians in a Seventh Day Adventist group. Am J Clin Nutr. 1986;21:853.

    Google Scholar 

  60. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232:34–47.

    Article  PubMed  CAS  Google Scholar 

  61. Keys A. Coronary heart disease in seven countries. Circulation. 1970;41 (suppl 1): 1–8.

    Google Scholar 

  62. Havel RJ. Classification of hyperlipidemias. Ann Rev Med. 1977;28:195–209.

    Article  PubMed  CAS  Google Scholar 

  63. Scanu AM. Lipoprotein (a): A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988; 112:1045–1047.

    PubMed  CAS  Google Scholar 

  64. Zenker G, Koltringer P, Bone G, et al. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942–945.

    Article  PubMed  CAS  Google Scholar 

  65. van Berkel JC, Bakkeren HF, Kuipers F, et al. In vivo evidence for reverse cholesterol transport from liver endothelial cells to parenchymal cells and bile by high density lipoproteins. Tenth International Symposium on Drugs Affecting Lipid Metabolism; November 8–11, 1989:47. Abstract 223.

    Google Scholar 

  66. Alam R, Yatsu FM, Tsui L, Alam S. Receptor-mediated uptake and “retroendocytosis” of high-density lipoproteins by cholesterol-loaded human monocyte-derived macrophages: possible role in enhancing reverse cholesterol transport. Biochimica et Biophysica Acta. 1989;1004:292–299.

    Article  PubMed  CAS  Google Scholar 

  67. Brunzell JD, Sniderman AD, Albers JJ, et al. Apoproteins B and A-I and coronary heart disease. Arteriosclerosis. 1984;4:79–83.

    Article  PubMed  CAS  Google Scholar 

  68. Wallentin L, Sundin B. HDL2 and HDL3 lipid levels in coronary heart disease and other causes. Atherosclerosis. 1986;59:3–104.

    Article  Google Scholar 

  69. Norum RA, Lakier JB, Goldstein S, et al. Familial deficiency of apolipoprotein A-I and C-III and precocious coronary heart disease. N Engl J Med. 1986; 306:1513–1519.

    Article  Google Scholar 

  70. Karathanasis SK, Zannis VI, Breslow JL. A DNA insertion in the human apoprotein A-I gene locus related to the development of atherosclerosis. Nature. 1983;301:718.

    Article  PubMed  CAS  Google Scholar 

  71. Rees A, Stocks J, Sharpe CR, et al. DNA polymorphism in the apoprotein A-I-CIII gene cluster. J Clin Invest. 1995;76:1090–1095.

    Article  Google Scholar 

  72. Roederer GD, Langlois YE, Jagar KA, et al. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke. 1984; 15:605–613.

    Article  PubMed  CAS  Google Scholar 

  73. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:81–86.

    Article  PubMed  CAS  Google Scholar 

  74. Bilheimer DW, Grundy SW, Brown MS, et al. Mevinolin and colestipol stimulate receptor-mediated clearance in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 1983;80: 4124–4128.

    Article  PubMed  CAS  Google Scholar 

  75. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. JAMA. 1982;248:1465–1477.

    Article  Google Scholar 

  76. Moore, TJ. The cholesterol myth. Atlantic Monthly. September 1989. pp 37–70.

    Google Scholar 

  77. Brett A. Treating hypercholesterolemia —how should practicing physicians interpret the published data for patients? N Engl J Med. 1989;321:676–680.

    Article  PubMed  CAS  Google Scholar 

  78. Leaf A. Management of hypercholesterolemia—are creative interventions advisable? TV Engl J Med. 321:680–684.

    Google Scholar 

  79. Mensink RP, Katan MB. Effects of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high density lipoprotein cholesterol in healthy women and men. N Engl J Med. 1989;321:436–441.

    Article  PubMed  CAS  Google Scholar 

  80. Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res. 1985;26:194–202.

    PubMed  CAS  Google Scholar 

  81. AHA Special Report. Recommendations for the treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation. 1984;69, 1065A.

    Google Scholar 

  82. Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080–2086.

    Article  Google Scholar 

  83. American Heart Association Committee Report. Rationale of the diet-heart statement of the American Heart Association. Circulation. 1982;65:839–854.

    Article  Google Scholar 

  84. Strategy for the Prevention of Coronary Heart Disease. A policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;8:77–88.

    Google Scholar 

  85. Hoeg JM, Gregg RE, Brewer HBV Jr. An approach to the management of hyperlipoproteinemias. JAMA. 1986;255:512.

    Article  PubMed  CAS  Google Scholar 

  86. Yatsu FM, Alam R, Alam S. Enhancement of cholesteryl ester metabolism in cultured human monocyte-derived macrophages by Verapamil. Biochim Biophys Acta. 1985;847:77–81.

    Article  PubMed  CAS  Google Scholar 

  87. Kramsch DM, Aspen AJ, Apstein CS. Suppression of experimental atherosclerosis by the calcium antagonist lanthanum. Possible role of calcium in atherogenesis. J Clin Invest. 1980;65:967–981.

    Article  PubMed  CAS  Google Scholar 

  88. Parmley WW, Blumlein S, Sievers R. Modification of experimental atherosclerosis by calcium channel blockers. Am J Cardiol. 1985;55:165B-171B.

    Article  PubMed  CAS  Google Scholar 

  89. Betz E, Hammerle H, Strohschneider T. Inhibition of smooth muscle cell proliferation and endothelial cell permeability with Flunarizine in vitro and in experimental atheromas. Res Exp Med. 1985; 185: 325–340.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Frank M. Yatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. DeGraba
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, Sunnybrook Health Science Centre, University of Toronto, Toronto, Ontario, M4N 3M5, Canada

    John W. Norris M.D.

  2. Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, N6A 5A5, Canada

    Vladimir C. Hachinski M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Yatsu, F.M., DeGraba, T.J. (1991). Prevention of Atherothrombotic Brain Infarction: Role of Lipids. In: Norris, J.W., Hachinski, V.C. (eds) Prevention of Stroke. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-4226-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-4226-8_3

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-4228-2

  • Online ISBN: 978-1-4757-4226-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation